Monoclonal Antibody Pharmacokinetics in Type 2 Diabetes Mellitus and Diabetic Nephropathy

The incidence of diabetes mellitus (DM) is increasing worldwide, and both type 1 as well as type 2 DM patients are at high risk of developing diabetic nephropathy (DN). Although the effects of DM and DN have been well documented for low molecular weight proteins and albumin, there is limited informa...

Full description

Saved in:
Bibliographic Details
Published in:Current pharmacology reports 2016-04, Vol.2 (2), p.45-56
Main Authors: Chadha, Gurkishan S., Morris, Marilyn E.
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Cancer Research
Molecular Drug Disposition (M Hu
Molecular Medicine
Pharmacology/Toxicology
Section Editor
Topical Collection on Molecular Drug Disposition
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of diabetes mellitus (DM) is increasing worldwide, and both type 1 as well as type 2 DM patients are at high risk of developing diabetic nephropathy (DN). Although the effects of DM and DN have been well documented for low molecular weight proteins and albumin, there is limited information regarding the changes in the clearance of higher molecular weight proteins, including monoclonal antibodies (mAbs) and IgG, an antibody isotype. This review compiles the available literature describing the effects of DM and DN on the pharmacokinetics and pharmacodynamics of IgG and mAbs and the potential mechanisms underlying the effects of DM and DN on IgG/mAb renal and catabolic clearances. This review also highlights the role of the neonatal Fc receptor (FcRn) and endocytic receptors (megalin and cubilin) and the influence of cytokines on renal function and expression/function of these proteins.
ISSN:2198-641X
2198-641X
DOI:10.1007/s40495-016-0048-z